Glabe Paper Helps Confirm Prana Drug Strategy

Posted: Apr. 2, 2009

A paper released on April 1, 2009, in the Journal of Neuroscience corroborates Prana’s strategy to treat Alzheimer’s disease patients.

Says Dr. Charles Glabe, an author of the paper and member of Cure Alzheimer’s Fund Research Consortium, “these results are very exciting news for understanding the mechanism of Alzheimer’s pathogenesis. They help elucidate the fundamental role of metal ions like zinc in causing the formation of Abeta oligomers which damage synapses.”

While this paper did not have Cure Alzheimer’s Fund support, nor has Cure Alzheimer’s Fund supported the work of  Prana, an Australian biotech company, the concepts involved have been central to investigations by Cure Alzheimer’s Fund’s Oligomer Collaborative, of which Dr. Glabe has been a part. (See the Oligomer Collaborative on our website. ) Please note that Dr. Rudy Tanzi, Chair of the Cure Alzheimer’s Fund Research Consortium, is a founder of  Prana and endorses its pursuit of therapeutic interventions through anti-Abeta oligomer drugs such as Prana’s PBT2.


Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients>